<DOC>
	<DOCNO>NCT02613208</DOCNO>
	<brief_summary>The purpose study identify powerful easy predictive/prognostic marker drive patient bevacizumab .</brief_summary>
	<brief_title>A Study Develop Predictive Prognostic Tools Optimizing Therapy With Bevacizumab Frontline Cancer Therapy Patients With Metastatic Her 2- Negative Aggressive Disease Criteria</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients age &gt; = 18 year Patients HER2negative MBC . Mandatory HER2/estrogen receptor ( ER ) /progesterone receptor ( PR ) status Patient meet criterion firstline treatment chemotherapy plus bevacizumab ( standard dos ) local , regional national guideline authority Patients measurable disease ( RECIST criterion v1.1 ) patient measurable assessable disease Molecular phenotype triple negative metastatic breast cancer ER [ + ] tumor need fulfill least one two clinical criterion ( metastatic relapse adjuvant endocrine therapy progression least one prior line endocrine therapy advance disease aggressive disease criterion [ least two criterion : taxane base regimen { neo } adjuvant setting , metastatic relapse within 2 year end chemotherapy early breast cancer , liver metastasis , three organ metastatic involvement , symptomatic visceral disease ] ) Eastern Cooperative Oncology Group ( ECOG ) 02 Signed informed consent form Patient receive prior chemotherapy metastatic disease Patient require major/minor surgery within 3 week prior administration first dose study treatment Patient receive investigational therapy within 4 week prior study entry Patient know symptomatic brain metastasis Patient nonmeasurable assessable disease , exclusive blastic bone disease , pleural , pericardial abdominal effusion evidence disease Patient chronic daily treatment corticosteroid ( dos &gt; 10 mg / day methylprednisolone equivalent ) , except inhaled steroid Pregnant breastfeed patient . A serum pregnancy test take 7 day prior study treatment , 14 day prior study treatment ( latter case another urine test take within 7 day prior study treatment confirm result ) Women childbearing potential ( define last menstrual period &lt; 2 year surgically sterilize ) use hormonal contraceptive highly effective birth control ( e.g . intrauterine device ) study Patient active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy Patient significant renal , hematological liver function alteration accord investigator 's criterion Patient serious medical risk factor involve major organ system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Bevacizumab</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Human Epidermal Growth Factor Receptor-Type 2</keyword>
</DOC>